Abstract #0616
A principled approach to select DCE-MRI derived radiomics features for evaluation in phase I/II trials
Michael Berks1, Damien J McHugh2, Nuria Porta3, Ross A Little1, Susan Cheung1, Gordon C Jayson4,5, Geoff J M Parker6,7, and James P B O'Connor1,8,9
1Quantitative Biomedical Imaging Laboratory, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom, 2Medical Physics, The Christie Hospital NHS Trust, Manchester, United Kingdom, 3Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom, 4Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom, 5Department of Medical Oncology, The Christie Hospital NHS Trust, Manchester, United Kingdom, 6Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom, 7Bioxydyn Ltd, Manchester, United Kingdom, 8Department of Radiology, The Christie Hospital NHS Trust, Manchester, United Kingdom, 9Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom
Synopsis
DCE-MRI biomarkers such as change in median Ktrans have a proven role in drug development in phase I/II trials. There is current interest in using approaches such as radiomics to extract additional information relating to spatial heterogeneity from images and one emerging application is to apply these analyses to clinical trial data where imaging is used to monitor pharmacodynamic change in the tumour microenvironment. Here, we explore the properties of radiomics features extracted from maps of Ktrans and aim to identify features that are repeatable at baseline, show consistent treatment effect and provide additional, independent information to the median Ktrans.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
